Prostate Cancer

Prostate cancer patients who chose active surveillance did not compromise their chances of a cure by waiting before they underwent radical prostatectomy, data from a Swedish registry showed.

Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.

New prostate cancer screening guidelines that seek to balance overtreatment concerns with the need to preserve gains in curbing prostate cancer mortality were unveiled at the National Comprehensive Cancer Network's 19th Annual Conference.

A rising prostate-specific antigen after surgery or radiation therapy for prostate cancer is not enough reason, on its own, to initiate androgen-deprivation therapy.

A recent study that followed men newly diagnosed with localized prostate cancer for a median 18 years found that immediate radical prostatectomy significantly cut death rates as compared with watchful waiting with treatment upon progression, especially in men with intermediate-risk disease.

Two recent studies have raised questions about current trends in prostate cancer (PC) treatment, one supporting the employment of a little-used strategy-direct treatment of the primary tumor in men who have metastatic PC at diagnosis

Despite being quite popular, the dietary supplements vitamin E and selenium do not protect men from developing prostate cancer, and in fact greatly increase risk in certain patients if taken at doses higher than those recommended

Evan Y. Yu, MD, from Seattle Cancer Care Alliance, discusses the association of alkaline phosphatase with outcomes in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, comments on current clinical trial endpoints in prostate cancer.

The combination of custirsen (OGX-011) with docetaxel and prednisone failed to significantly extend survival as a first-line treatment for men with metastatic castration-resistant prostate cancer

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, describes imaging approaches in prostate cancer

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses the results of a retrospective analysis of the effect of prior abiraterone use on the activity level of enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC).

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses prostate cancer biopsies.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.

Patients with localized prostate cancer at intermediate or high risk for progression experience better outcomes when 6 months of androgen deprivation therapy is added to standard radiotherapy.

A novel 100-locus DNA signature obtained from pretreatment biopsies accurately classified 75% of patients with untreated prostate cancer as low- or high-risk.

Robert Dreicer, MD, MS, discusses next-generation anti-androgen therapies for patients with castration-resistant prostate cancer.

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses the molecular characterization of circulating tumor cells (CTCs) in neuroendocrine-positive prostate cancer.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses novel imaging modalities in prostate cancer.

An interview with Padmanee Sharma, MD, PhD, on the evolving field of immunotherapy for patients with castration-resistant prostate cancer.

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses valuable prognostic and predictive tests to help urologists determine when to biopsy, when to rebiopsy, and how to direct treatment for patients with a positive biopsy.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a trial that would study Provenge (sipuleucel-T) in combination with radium-223 as a potential treatment option for patients with prostate cancer.

Ian M. Thompson, MD, director, professor, Department of Urology, Cancer Therapy & Research Center, The University of Texas Health Science Center, discusses the problems with prostate biopsies and some possible solutions.

Richard S. Pelman, MD, president of the American Association of Clinical Urologists and an urologist at the University of Washington Department of Urology, discusses techniques for selecting patients for radical prostatectomy or watchful waiting and active surveillance.

Robert Dreicer, MD, MS, discusses combining and sequencing agents with immunotherapies for the treatment of prostate cancer.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses a phase III trial measuring the efficacy of custirsen plus docetaxel versus docetaxel alone in patients with prostate cancer (SYNERGY trial).

William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial in metastatic castrate-resistant prostate cancer (mCRPC).

Men with clinically localized prostate cancer who were treated with radiotherapy were more likely, over the subsequent 5 years, to be admitted to a hospital, undergo rectal, anal, or open surgical procedures, or develop secondary malignancies than men treated with radical prostatectomy

Increasing efficacy with immunotherapies in some cancers led to the strategy being deemed Breakthrough of the Year by Science magazine in 2013